REDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Arrowhead Pharmaceuticals’ REDEMPLO Gains NICE Recommendation for NHS Treatment of Familial Chylomicronaemia Syndrome in England and Wales Arrowhead Pharmaceuticals’ REDEMPLO® (plozasiran) has received a positive funding recommendation from the National…

Read MoreREDEMPLO® (Plozasiran) Offers New Triglyceride-Lowering Treatment Option for Adults with FCS in England and Wales

Avanzanite Bioscience Strengthens UK Operations with Appointment of Sarah O’Connell as Country Manager

Avanzanite Bioscience Expands UK Operations, Appoints Sarah O’Connell as Country Manager to Strengthen Rare Disease Medicine Access Avanzanite Bioscience B.V., a European pharmaceutical company specializing in rare diseases, has announced…

Read MoreAvanzanite Bioscience Strengthens UK Operations with Appointment of Sarah O’Connell as Country Manager

Powerful Medical Secures CPT Code for AI-Powered Heart Attack Detection Following FDA Authorization of Queen of Hearts™

Powerful Medical Secures New CPT Code for Queen of Hearts AI ECG Technology to Detect Heart Attacks Powerful Medical, a company specializing in artificial intelligence (AI)-driven cardiovascular diagnostics, has announced…

Read MorePowerful Medical Secures CPT Code for AI-Powered Heart Attack Detection Following FDA Authorization of Queen of Hearts™

Rumi Therapeutics Licenses IND-Ready PDE2 Inhibitor RTX-7340 to Enthorin Therapeutics for Fragile X Syndrome Development

Rumi Therapeutics Secures Option to License Enthorin’s IND-Ready PDE2 Inhibitor for Fragile X Syndrome Rumi Therapeutics, a drug-development company operating within Rumi Scientific Holdings, has announced an option-to-license agreement with…

Read MoreRumi Therapeutics Licenses IND-Ready PDE2 Inhibitor RTX-7340 to Enthorin Therapeutics for Fragile X Syndrome Development